KCPG
PTCT icon

Kavar Capital Partners Group’s PTC Therapeutics PTCT Stock Holding History

Kavar Capital Partners Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5
Closed – – 514
2015
Q3 		$0 Buy
+5
New +$214 ﹤0.01% 522

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Kavar Capital Partners Group's PTCT Position: Q4 2015 in Review

Kavar Capital Partners Group sold out of PTC Therapeutics (PTCT) in Q4 2015, closing a stake of 5 shares.

Kavar Capital Partners Group first reported a position in PTCT in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 141 funds tracked by Wall St. Rank hold PTCT as of Q4 2015.

  • Kavar Capital Partners Group reported no remaining PTC Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Kavar Capital Partners Group sold 5 PTC Therapeutics shares in Q4 2015.
  • Kavar Capital Partners Group first reported a position in PTC Therapeutics in Q3 2015 and held it in 1 quarter.
  • Kavar Capital Partners Group's PTC Therapeutics position peaked at $0 in Q3 2015.
  • 141 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2015.

Based on Kavar Capital Partners Group's 13F filing for Q4 2015, filed 1 May 2019.